Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception

Trial Profile

Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2015

At a glance

  • Drugs Ethinylestradiol/drospirenone/levomefolic acid (Primary) ; Levomefolic acid
  • Indications Pregnancy
  • Focus Pharmacodynamics; Registrational
  • Sponsors Bayer
  • Most Recent Events

    • 22 Aug 2014 Planned primary completion date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 22 Aug 2014 Planned End Date changed from 1 Mar 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 21 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top